Staley Capital Advisers Inc Bristol Myers Squibb CO Transaction History

Staley Capital Advisers Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 08, 2020	SELL	$46.4 - $67.43 $305,729 - $444,296	-6,589 Closed	0 $0
Q4 2019 Feb 04, 2020	BUY	$49.21 - $64.19 $25,835 - $33,699	525 Added 8.66%	6,589 $423,000
Q3 2019 Nov 08, 2019	SELL	$42.77 - $50.71 $24,378 - $28,904	-570 Reduced 8.59%	6,064 $308,000
Q2 2019 Aug 09, 2019	BUY	$44.62 - $49.34 $1,293 - $1,430	29 Added 0.44%	6,634 $301,000
Q1 2019 May 10, 2019	BUY	$45.12 - $53.8 $4,105 - $4,895	91 Added 1.4%	6,605 $315,000
Q4 2018 Feb 05, 2019	BUY	$48.76 - $63.23 $1,267 - $1,643	26 Added 0.4%	6,514 $339,000
Q3 2018 Nov 09, 2018	BUY	$55.19 - $62.25 $1,214 - $1,369	22 Added 0.34%	6,488 $403,000
Q2 2018 Aug 08, 2018	BUY	$50.53 - $62.98 $31,581 - $39,362	625 Added 10.7%	6,466 $358,000
Q1 2018 May 09, 2018	SELL	$59.92 - $68.98 $58,721 - $67,600	-980 Reduced 14.37%	5,841 $369,000
Q4 2017 Feb 12, 2018	SELL	$59.94 - $65.35 $58,741 - $64,042	-980 Reduced 12.56%	6,821 $418,000
Q3 2017 Nov 09, 2017	BUY	$55.23 - $63.74 $45,122 - $52,075	817 Added 11.7%	7,801 $497,000
Q2 2017 Aug 14, 2017	BUY	N/A	6,984	6,984 $389,000

2,536

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $120B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Staley Capital Advisers Inc, based on Form 13F filings with the SEC.

Stay updated on Staley Capital Advisers Inc with notifications on news.